Where do Celldex Therapeutics's ratios come from?

Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-35,688.5%-17,101pp	-18,587.7%-8,732pp	-9,855.4%-5,802pp	-4,053.7%-1,180pp	-2,873.5%-94.6pp
Net margin	-32,753.6%-16,016pp	-16,737.2%-8,101pp	-8,635.8%-5,189pp	-3,446.9%-1,081pp	-2,366.1%-117pp
EBITDA margin	-35,299.7%-16,931pp	-18,369.1%-8,644pp	-9,725.3%-5,729pp	-3,995.9%-1,166pp	-2,830.3%-96.6pp
Free cash flow margin	-26,125.8%-12,306pp	-13,820.1%-6,833pp	-6,987.3%-3,733pp	-3,254.8%-961pp	-2,293.3%-18.4pp
Returns
Return on equity	-48.9%-8.3pp	-40.6%-8.2pp	-32.4%-5.3pp	-27.2%-4.0pp	-23.2%+3.6pp
Return on assets	-45.4%-7.7pp	-37.6%-7.1pp	-30.5%-4.6pp	-26%-3.7pp	-22.2%+2.9pp
Return on invested capital	-55.6%-8.6pp	-47%-8.1pp	-38.9%-5.6pp	-33.3%-2.6pp	-30.7%+4.2pp
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	8.9×-1.6×	10.5×-2.5×	13×-6.7×	19.7×-2.0×	21.7×+2.8×
Quick ratio	8.9×-1.6×	10.5×-2.5×	13×-6.7×	19.7×-2.0×	21.7×+2.8×
Cash ratio	0.7×+0.1×	0.6×-0.2×	0.8×+0.1×	0.7×+0.2×	0.5×-0.2×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Per Share
Book value per share	$6.85-13.6%	$7.94-11.9%	$9.01-8.7%	$9.87-6.8%	$10.59-8.7%
Valuation
Market capitalization	$2.11B+17.0%	$1.8B+5.1%	$1.72B+19.5%	$1.44B+19.3%	$1.2B-28.1%
Enterprise value	$2.08B+16.8%	$1.78B+5.6%	$1.68B+18.8%	$1.42B+19.0%	$1.19B-27.9%
Price / sales	2,438.2×+1,271×	1,167.4×+507×	660.7×+413×	248.2×+88.8×	159.4×-79.4×
Price / book	4.6×+1.2×	3.4×+0.6×	2.9×+0.7×	2.2×+0.5×	1.7×-0.5×
EV / sales	2,399.1×+1,249×	1,150.2×+502×	647.9×+403×	244.8×+87.2×	157.6×-77.7×
Free cash flow yield	-10.7%+1.1pp	-11.8%-1.3pp	-10.6%+2.5pp	-13.1%+1.3pp	-14.4%-4.9pp
Earnings yield	-13.4%+0.9pp	-14.3%-1.3pp	-13.1%+0.8pp	-13.9%+1.0pp	-14.8%-5.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Celldex Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

Where do Celldex Therapeutics's ratios come from?: Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.